Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Diabetes Insipidus I: Introduction01:29

Diabetes Insipidus I: Introduction

Definition Diabetes insipidus is a disorder marked by the production of large amounts of dilute urine because of impaired vasopressin production, release, or kidney response. The lack of effective vasopressin action limits water reabsorption in the renal collecting ducts, which leads to excessive urinary water loss and intense thirst.Clinical PresentationIndividuals with diabetes insipidus report persistent thirst and very high urine output. In severe cases, fluid intake can reach up to 20...
Diabetes Insipidus II: Pathophysiology01:22

Diabetes Insipidus II: Pathophysiology

Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.

Clinical lung cancer·2024
Same author

A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin.

Current oncology (Toronto, Ont.)·2020
Same author

Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2020
Same author

Neurotoxicity Among Survivors of Testicular Cancer: A Population-based Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019
Same author

Supraglenoid tubercle fractures repair with transverse locking compression plates in 4 horses.

Veterinary surgery : VS·2017
Same author

Extending standard testing period in honeybees to predict lifespan impacts of pesticides and heavy metals using dynamic energy budget modelling.

Scientific reports·2016
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Culturing Primary Rat Inner Medullary Collecting Duct Cells
06:11

Culturing Primary Rat Inner Medullary Collecting Duct Cells

Published on: June 21, 2013

Desmopressin.

D W Richardson, A G Robinson

    Annals of Internal Medicine
    |August 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Desmopressin (dDAVP) is a synthetic vasopressin analog with superior antidiuretic effects and longer action. It effectively treats central diabetes insipidus and aids in managing mild hemophilia and von Willebrand

    More Related Videos

    Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
    08:44

    Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

    Published on: September 1, 2016

    Detrusor Underactivity Model in Rats by Conus Medullaris Transection
    03:26

    Detrusor Underactivity Model in Rats by Conus Medullaris Transection

    Published on: August 28, 2020

    Related Experiment Videos

    Last Updated: Jun 20, 2026

    Culturing Primary Rat Inner Medullary Collecting Duct Cells
    06:11

    Culturing Primary Rat Inner Medullary Collecting Duct Cells

    Published on: June 21, 2013

    Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
    08:44

    Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

    Published on: September 1, 2016

    Detrusor Underactivity Model in Rats by Conus Medullaris Transection
    03:26

    Detrusor Underactivity Model in Rats by Conus Medullaris Transection

    Published on: August 28, 2020

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Hematology

    Background:

    • Desmopressin (dDAVP) is a synthetic analog of arginine vasopressin.
    • It exhibits enhanced antidiuretic potency and reduced pressor activity.
    • dDAVP possesses a prolonged half-life and duration of action compared to natural vasopressin.

    Purpose of the Study:

    • To summarize the properties and therapeutic applications of desmopressin.
    • To highlight its efficacy in central diabetes insipidus.
    • To discuss its role in managing mild classical hemophilia and von Willebrand's disease.

    Main Methods:

    • Review of pharmacological properties of desmopressin.
    • Analysis of clinical data for central diabetes insipidus treatment.
    • Evaluation of desmopressin's efficacy in bleeding disorders.

    Main Results:

    • Desmopressin demonstrates superior antidiuretic effects and reduced pressor activity.
    • It is the preferred treatment for central diabetes insipidus via intranasal or parenteral administration.
    • dDAVP effectively increases factor VIII and von Willebrand's factor levels for surgical procedures.

    Conclusions:

    • Desmopressin is a valuable therapeutic agent with a favorable pharmacological profile.
    • Its established efficacy in central diabetes insipidus is complemented by new applications in hematology.
    • The drug's ability to transiently elevate coagulation factors makes it crucial for specific surgical interventions.